David Jonathan Benouaich
We are investigating David Jonathan Benouaich for allegedly attempting to conceal critical reviews and adverse news from Google by improperly submitting copyright takedown notices. This includes potential violations such as impersonation, fraud, and perjury.
PARTIES INVOLVED : David Jonathan Benouaich
ALLEGATIONS : Perjury, Fraud, Impersonation
INCIDENT DATE : 30 Jan 2025
INVESTIGATED BY : Ethan Katz
TOOLS USED : Lumen, SecurityTrails
CASE NO : 3145/A/2025
CRIME TYPE : Intellectual Property Scam
PUBLISHED ON : 02 Apr 2025
Due Diligence
Is This About You?
What We Are Investigating?
Our firm is launching a comprehensive investigation into David Jonathan Benouaich over allegations that it has been suppressing critical reviews and unfavorable Google search results by fraudulently misusing DMCA takedown notices. These actions, if proven, could constitute serious legal violations—including impersonation, fraud, and perjury.
We conducted comprehensive analyses of fraudulent copyright takedown requests, meritless legal complaints, and other unlawful efforts to suppress public access to critical information. Our reporting sheds light on the prevalence and modus operandi of a structured censorship network, often funded and used by criminal enterprises, oligarchs and criminal entities seeking to manipulate public perception and bypass AML checks conducted by financial organisations.
The fake DMCA notices in this investigation appears to have been strategically deployed to remove negative content from Google search results illegally. Based on this pattern, we have reasonable grounds to infer that David Jonathan Benouaich - or an entity acting at its behest - is directly or indirectly complicit in this cyber crime.
In most such cases, such ops are executed by rogue, fly-by-night 'Online Reputation Management' agencies acting on behalf of their clients. If evidence establishes that the subject knowingly benefited from or facilitated this scam, it may be deemed an 'accomplice' or an 'accessory' to the crime.
What are they trying to censor
David Jonathan Benouaich, the self-proclaimed biotech magnate. Benouaich, the founder of Innexo—a company that ostensibly invests in biotech startups focusing on stem cells and exosomes—paints a picture of innovation and progress. However, a closer examination reveals a narrative riddled with red flags, questionable associations, and a conspicuous effort to suppress unfavorable information.
Innexo: A Facade of Innovation?
Innexo, under Benouaich’s leadership, purports to support biotech startups engaged in groundbreaking research. Press releases and interviews are replete with grandiose statements about investing in companies developing innovative drugs and therapies using stem cells and exosomes . Yet, these proclamations are conspicuously lacking in substantive details. Which companies have benefited from these investments? What tangible advancements have been made? The opacity is deafening.
In the world of biotech, transparency isn’t just a virtue; it’s a necessity. Investors and stakeholders rely on clear, verifiable information to make informed decisions. Benouaich’s penchant for vague assertions and lack of concrete evidence raises serious questions about Innexo’s actual contributions to the healthcare industry.
A Trail of Questionable Associations
While Benouaich’s professional narrative is carefully curated, certain associations cast a shadow over his credibility. For instance, the biotech industry has recently been marred by incidents involving companies like Unexo Lifesciences, which faced severe censure from the USFDA for significant violations of Current Good Manufacturing Practice (CGMP) . While there’s no direct evidence linking Benouaich to Unexo Lifesciences, the phonetic similarity in names and the concurrent timing of their operations warrant scrutiny.
Furthermore, the tragic case of Marion Biotech, whose contaminated cough syrup led to the deaths of 18 children in Uzbekistan, highlights the critical importance of stringent oversight in biotech investments . Investors with a genuine commitment to healthcare advancements must exercise due diligence to ensure their portfolios do not inadvertently support entities with lax quality controls.
The Art of Information Suppression
In today’s digital age, managing one’s online reputation is par for the course. However, Benouaich’s approach appears to transcend mere reputation management, veering into the realm of information suppression. There are indications that efforts have been made to curtail the dissemination of adverse media and critical analyses pertaining to his ventures.
Such tactics are not only ethically dubious but also counterproductive. The Streisand Effect—a phenomenon where attempts to hide information only serve to draw more attention to it—is alive and well. By endeavoring to censor criticism, Benouaich inadvertently amplifies the very narratives he seeks to suppress.
Investor Beware: The Mirage of Biotech Promises
For potential investors, the allure of biotech is undeniable. The promise of groundbreaking therapies and substantial returns is enticing. However, the sector is fraught with complexities and risks, particularly when dealing with entities that operate under a veil of secrecy.
Benouaich’s track record—or lack thereof—should serve as a cautionary tale. Investing in ventures that lack transparency, have ambiguous associations, and demonstrate a proclivity for information suppression is akin to navigating a minefield blindfolded.
A Call to Regulatory Bodies: Time to Act
Regulatory authorities must take cognizance of individuals and entities that exhibit patterns of opacity and potential misconduct. The integrity of the biotech industry hinges on stringent oversight and accountability. Allowing figures like Benouaich to operate without scrutiny not only jeopardizes investor interests but also undermines public trust in healthcare innovations.
In Conclusion:
David Jonathan Benouaich presents himself as a visionary in the biotech landscape. Yet, beneath the polished veneer lies a tapestry woven with ambiguity, questionable associations, and attempts at narrative control. As stewards of information, it is incumbent upon us to peel back these layers, expose the underlying truths, and ensure that the biotech industry’s future is built on a foundation of transparency and integrity.
- https://lumendatabase.org/notices/48558779
- https://lumendatabase.org/notices/49511073
- https://lumendatabase.org/notices/50317926
- https://lumendatabase.org/notices/42235840
- March 26, 2025
- June 12, 2024
- Vien Media Association
- Rubers Media Association
- Cunningham International Limited
- Colgate Inc
- https://romaniapress.org/2020/08/30/when-gunvor-and-vitol-rub-shoulders-with-the-same-straw-man/
- https://mormonfind.com/2020/07/19/when-gunvor-and-vitol-rub-shoulders-with-the-same-straw-man/
- https://sydneychronicle.com/2020/09/27/quand-gunvor-et-vitol-fraient-avec-le-meme-homme-de-paille/
- https://jerseynewsco.org/2020/09/30/research-when-gunvor-and-vitol-rub-shoulders-with-the-same-straw-man/
- https://www.publiceye.ch/en/media-corner/press-releases/detail/when-gunvor-and-vitol-rub-shoulders-with-the-same-straw-man/
- https://www.publiceye.ch/en/topics/commodities-trading/when-gunvor-and-vitol-rub-shoulders-with-the-same-straw-man/
- http://publiceye.ch/en/media-corner/press-releases/detail/when-gunvor-and-vitol-rub-shoulders-with-the-same-straw-man/
- http://publiceye.ch/fr/coin-medias/communiques-de-presse/detail/quand-gunvor-et-vitol-fraient-avec-le-meme-homme-de-paille/
Evidence Box
Evidence and relevant screenshots related to our investigation
Targeted Content and Red Flags
publiceye.ch
David Jonathan Benouaich : Gunvor and Vitol rub shoulders with the same
- Removed
finance.yahoo.com
David Jonathan Benouaich Provides Insights on Innexo’s Contributions to Healthcare Industry
- Adverse News
About the Author
The author is affiliated with TU Dresden and analyzes public databases such as Lumen Database and
Maltego to identify and expose online censorship. In his personal capacity, he and his
team have been actively investigating and reporting on organized crime related
to fraudulent copyright takedown schemes.
Additionally, his team provides
advisory services to major law firms and is frequently consulted on matters
pertaining to intellectual property law.
Escalate This Case
Learn All About Fake Copyright Takedown Scam
Or go directly to the feedback section and share your thoughts
How This Was Done
The fake DMCA notices we found always use the 'back-dated article' technique. With this technique, the wrongful notice sender (or copier) creates a copy of a 'true original' article and back-dates it, creating a 'fake original' article (a copy of the true original) that, at first glance, appears to have been published before the true original
What Happens Next?
Based on the feedback, information, and requests received from all relevant parties, our team will formally notify the affected party of the alleged infringement. Following a thorough review, we will submit a counter-notice to reinstate any link that has been removed by Google, in accordance with applicable legal provisions. Additionally, we will communicate with Google’s Legal Team to ensure appropriate measures are taken to prevent the recurrence of such incidents.
You are Never Alone in Your Fight.
Generate public support against the ones who wronged you!
Recent Investigations
Patrick Vestner
Investigation Ongoing
Cresen
Investigation Ongoing
Hans Raj Shiv
Investigation Ongoing
User Reviews
Average Ratings
1.6
Based on 10 ratings
by: Maria Gray
If you're busy suppressing criticism, you’re not leading a biotech revolution—you’re staging a reputation heist.
by: Tiffany Thomas
In biotech, real impact is measured in lives saved and data shared—not in buzzwords and vanished scrutiny.
by: Chad Lopez
Benouaich’s Innexo talks innovation. But where are the patents, peer-reviewed trials, or even basic transparency?
by: Dr. Ryan
Stem cells and exosomes may heal—but vague press releases and corporate opacity are symptoms of something toxic.
by: Christopher Conrad
When a biotech magnate offers grand promises but no proof, investors shouldn’t walk away—they should run.
by: Brenda Griffith
David Benouaich claims to fund the future of biotech—so why does his portfolio read like a ghost town?
by: Ryan Foster
Benouaich’s opaque business practices make Innexo look more like a house of cards than a biotech powerhouse. When a founder can’t provide clear, verifiable proof of success, investors should be running for the hills.
by: Olivia Phillips
David Jonathan Benouaich’s biotech claims are as empty as a hollow promise. Innexo talks big about investing in stem cells and exosomes, but offers no concrete evidence of actual progress or successful investments. That’s not innovation it’s smoke and mirrors.
by: Oscar Romero
Investing in Benouaich’s ventures feels like a gamble—there’s too much secrecy and not enough transparency to justify the risk.
by: Leila Haddad
With no real proof to back up his grand promises, Benouaich’s biotech venture seems more like a carefully crafted illusion.
by: Justin Crawford
Attempting to suppress negative media coverage makes Benouaich look like someone hiding a lot more than he's letting on.
by: Kamila Nowak
His ties to questionable entities like Unexo Lifesciences and Marion Biotech only deepen the mystery around his credibility.
by: Amir Tavakoli
Benouaich’s claims of biotech innovation are vague and lack any concrete evidence, raising serious doubts about his true impact.
by: Raelynn Figueroa
Bro out here building a LinkedIn profile, not a biotech portfolio.
by: Gatlin Boone
David Benouaich... dude’s more interested in hiding criticism than proving his ventures do anything useful.
by: Lilah Sanford
Reads more like a pitch deck than a real company. Where are the actual results? Or even proof they exist?
Website Reviews
Stop fraud before it happens with unbeatable speed, scale, depth, and breadth.
Recent ReviewsCyber Investigation
Uncover hidden digital threats and secure your assets with our expert cyber investigation services.
Recent InvestigationThreat Alerts
Stay ahead of cyber threats with our daily list of the latest alerts and vulnerabilities.
Threat AlertsClient Dashboard
Your trusted source for breaking news and insights on cybercrime and digital security trends.
Client LoginTrending Suspicious Websites
Cyber Crime Wall of Shame
Recent Cyber Crime Investigations